Applied BioCode (TPE:6598) Other Stockholders Equity: NT$-4.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6598 Applied BioCode Corp TPE:6598
75 GF Score
Price NT$26.15
GF Value NT$23.34
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Applied BioCode Other Stockholders Equity?

Applied BioCode TPE:6598 +9.87% 75 Other Stockholders Equity is NT$-4.3 Mil as of Dec. 2025. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$23.34 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Applied BioCode's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$-4.3 Mil.

Applied BioCode's quarterly Other Stockholders Equity increased from Jun. 2025 (NT$-34.4 Mil) to Sep. 2025 (NT$-23.5 Mil) and increased from Sep. 2025 (NT$-23.5 Mil) to Dec. 2025 (NT$-4.3 Mil).

Applied BioCode's annual Other Stockholders Equity increased from Dec. 2023 (NT$-7.3 Mil) to Dec. 2024 (NT$32.6 Mil) but then declined from Dec. 2024 (NT$32.6 Mil) to Dec. 2025 (NT$-4.3 Mil).

Applied BioCode Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Applied BioCode's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Applied BioCode Other Stockholders Equity Chart

Applied BioCode Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100.71 -10.88 -7.34 32.65 -4.31

Applied BioCode Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.65 43.19 -34.44 -23.55 -4.31
TPE:6598
75GF Score
Applied BioCode Corp TPE:6598
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Applied BioCode Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-4.3 Mil mean?
Applied BioCode (TPE:6598) has a Other Stockholders Equity of NT$-4.3 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Applied BioCode and its competitors.
Is Applied BioCode's Other Stockholders Equity too high?
Applied BioCode's current Other Stockholders Equity is NT$-4.3 Mil. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Other Stockholders Equity compare to ABT and SYK?
Applied BioCode's Other Stockholders Equity of NT$-4.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Applied BioCode and its competitors. Applied BioCode's current Other Stockholders Equity is NT$-4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$26.15 — trading 12% above its estimated fair value. The current Other Stockholders Equity is NT$-4.3 Mil. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Other Stockholders Equity is NT$-4.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Applied BioCode (TPE:6598) Overvalued in 2026?

Based on GuruFocus' analysis, Applied BioCode stock appears to be overvalued. The current stock price of NT$26.15 is trading 12% above its estimated GF Value™ of NT$23.34. GuruFocus considers Applied BioCode to be Modestly Overvalued.

Key valuation signals for TPE:6598:

  • Other Stockholders Equity: NT$-4.3 Mil
  • GF Value™: NT$23.34 vs. price of NT$26.15 (12% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Applied BioCode Business Description

Address 12130 Mora Dr., Unit 2, Santa Fe Springs, CA, USA, 90670
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score

Get the complete analysis for TPE:6598

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.15
Price
NT$23.34
GF Value